Ibogaine for Chronic Pain: What the Evidence Shows

Chronic pain is pain persisting beyond three months. It is not simply acute pain that lasts longer — in many cases the nervous system itself has changed, and pain becomes a condition rather than a symptom.

Using the 2023 National Health Interview Survey, the National Center for Health Statistics reported that 24.3% of US adults had chronic pain in the prior three months, and 8.5% had high-impact chronic pain — pain that limited life or work activities most days or every day. Prevalence rose sharply with age, from 12.3% in adults aged 18–29 to 36.0% in adults 65 and older.

Clinicians usually separate three mechanisms:

• Nociceptive pain — tissue damage or inflammation signalling normally, as in osteoarthritis
• Neuropathic pain — pain caused by a lesion or disease of the somatosensory nervous system: diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy, nerve root avulsion, and complex regional pain syndrome (CRPS). It is typically described as burning, electric, or shooting, often with allodynia (pain from normally painless touch)
• Nociplastic pain — pain arising from altered central processing without identifiable tissue or nerve damage. Fibromyalgia, which affects roughly 1–2% of the general population, is the prototype, with widespread pain, fatigue, sleep disruption, and cognitive difficulty

Two facts frame everything that follows. First, chronic pain is subjective and self-reported, with no objective biomarker. Second, chronic pain trials show unusually large placebo responses. Both make uncontrolled reports of improvement genuinely difficult to interpret.

Conventional pain medicine has real evidence behind it — and is honest about how limited its effects are.

Neuropathic pain. The NeuPSIG systematic review and meta-analysis (Finnerup and colleagues, Lancet Neurology, 2015) pooled decades of randomised, double-blind trials and issued strong first-line recommendations for tricyclic antidepressants, SNRIs (mainly duloxetine), pregabalin, and gabapentin. The effect sizes are modest: a combined number needed to treat (NNT) of 6.4 for SNRIs and 7.7 for pregabalin to achieve at least 50% pain relief beyond placebo. Second- and third-line options include topical lidocaine, capsaicin 8% patches, tramadol, and — with weak recommendations — strong opioids and botulinum toxin A.

The authors attributed these moderate results to "modest efficacy, large placebo responses, heterogeneous diagnostic criteria, and poor phenotypic profiling."

Fibromyalgia. EULAR's recommendations place non-pharmacological management first, with graded aerobic and strengthening exercise as the strongest single recommendation, supported by cognitive behavioural therapy and multicomponent programmes. Where drugs are used, duloxetine, milnacipran, pregabalin, and amitriptyline have the best supporting data, again with modest average benefit.

Opioids. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain recommends non-opioid therapies as preferred for subacute and chronic pain, notes that evidence for long-term opioid benefit is limited, and warns explicitly that policies should not result in rapid tapering or abrupt discontinuation, which is associated with patient harm.

This is the honest baseline: partial relief for a minority, achieved safely, across thousands of randomised participants. It is a low bar in absolute terms — and a high one in evidentiary terms.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga, studied chiefly as an experimental intervention for substance use disorders. Interest in ibogaine for chronic pain rests almost entirely on mechanistic reasoning, and the reasoning is genuinely interesting.

Ibogaine acts across several systems relevant to pain processing:

• NMDA receptor antagonism. NMDA receptors drive central sensitisation, wind-up, and opioid tolerance. Ketamine, memantine, and dextromethorphan all exploit this target
• Kappa-opioid receptor activity. Noribogaine, ibogaine's long-lived metabolite, is a G-protein biased kappa-opioid receptor agonist. KOR agonists are analgesic in animal models, though classical KOR agonists cause dysphoria and sedation
• 5-HT2A and serotonergic action. The serotonergic system contributes to descending pain modulation, the same pathway invoked for psilocybin and LSD in pain
• Sigma-2 receptor binding and neurotrophic signalling. Ibogaine increases GDNF and BDNF expression in rodent dopaminergic regions, which has prompted speculation about nerve repair

The idea is old. In 1999 the US Patent and Trademark Office granted US Patent 5,925,634, "Use of ibogaine for treating neuropathic pain," to John W. Olney and Washington University, arguing that ibogaine was an NMDA antagonist without the neurotoxicity of others in its class.

The evidence-honest reading matters here. A patent is a legal claim, not clinical proof. The GDNF nerve regeneration hypothesis is drawn from studies of reward circuitry, not sensory neurons or dorsal horn plasticity. And no published work demonstrates that ibogaine reverses nerve damage in humans. These are plausible targets, not demonstrated pathways.

Start with the negative finding, because it is the most important one: no randomised controlled trial of ibogaine for chronic pain, neuropathic pain, or fibromyalgia has been completed or registered. Registered ibogaine trials target opioid use disorder, PTSD, traumatic brain injury, and depression. We could identify no published case report of ibogaine for complex regional pain syndrome and none for fibromyalgia.

The peer-reviewed clinical literature on ibogaine for neuropathic pain consists of one case report of one patient.

Dickinson, Dominguez Inzunza, Perez-Villa, Millar and Pushparaj published it in Frontiers in Pain Research in 2023. The patient was a 53-year-old man with roughly 20 years of intractable pain from C5–C7 brachial plexus nerve root avulsion, who had failed gabapentin, tramadol, oxycodone, methadone, and tricyclics despite multiple reconstructive surgeries.

Treatment ran across four phases over 85 days — a 13.03 mg/kg flood dose, a low-dose outpatient phase, a 42.27 mg/kg cumulative "saturation" protocol, then daily maintenance — for cumulative exposure of 125.7 mg/kg. Across five validated pain instruments (DN4, NPSI, NPQ, NPS, painDETECT), the authors reported a 72.2% reduction after the flood dose, 91% after saturation, and 71–80% sustained through two months.

The limitations are decisive:

• n = 1, unblinded, uncontrolled, with self-reported outcomes in a condition with a large placebo response
• All five authors were affiliated with Ambio Life Sciences, the treatment provider — a conflict of interest readers should weigh
• The authors cautioned that high-dose adverse effects "may limit tolerability of this saturation protocol to the most refractory cases"
• Follow-up ended at 85 days; durability is unknown

This is a hypothesis-generating observation in one extreme, refractory case — not evidence that ibogaine treats chronic pain.

The most substantive iboga-related pain science is not about ibogaine at all. It concerns synthetic analogues engineered specifically to remove ibogaine's psychedelic effects and cardiac liability — which is itself a comment on ibogaine.

Ibogalogs. Arias and colleagues (Biomedicine & Pharmacotherapy, 2024) tested three non-hallucinogenic iboga-derived compounds — tabernanthalog, ibogainalog, and ibogaminalog (DM506) — in mice. In the chronic constriction injury model of neuropathic pain and a colitis model of visceral pain, all three reduced mechanical hyperalgesia and allodynia dose-dependently, through a mechanism involving 5-HT2A receptor activation. A 2025 follow-up implicated crosstalk between 5-HT2A and mGlu2 receptors.

Oxa-noribogaine. Havel, Kruegel, Bechand and colleagues (Nature Communications, 2024) reported that this analogue is a potent kappa-opioid agonist with antinociceptive potency comparable to the reference agonist U50,488, and that a single 30 mg/kg dose produced complete reversal of opioid-induced hyperalgesia at six hours in mice.

The cardiac comparison in that paper is the most instructive detail on this page. Oxa-noribogaine and noribogaine bind the hERG channel with nearly identical affinity (Ki 2.1 µM vs 2.0 µM) — yet in adult human primary cardiomyocytes, noribogaine showed concentration-dependent pro-arrhythmic risk from 1 µM, while oxa-noribogaine showed none up to 10 µM.

None of these compounds is approved, and all results are in rodents. But the direction of the field is clear: researchers pursuing iboga pharmacology for pain are deliberately designing ibogaine's psychoactivity and arrhythmia risk out of the molecule.

A large share of people who contact ibogaine clinics about pain are not primarily seeking analgesia. They are seeking a way off long-term opioid therapy while still having pain.

This is a real and underserved clinical problem. Long-term opioid therapy for chronic pain often produces tolerance, dose escalation, and in some patients opioid-induced hyperalgesia — a state in which opioids paradoxically increase pain sensitivity. Tapering is difficult, and abrupt discontinuation is dangerous.

Ibogaine's best-documented effect in humans is attenuation of opioid withdrawal, and preclinical work suggests it can reverse morphine tolerance, consistent with NMDA antagonism. Its analogues reverse opioid-induced hyperalgesia in rodents. These findings are relevant to the tapering problem.

But several distinctions must be kept clear:

• Reducing withdrawal is not the same as treating pain. A person whose opioid dependence resolves may still have the underlying neuropathy or fibromyalgia
• Ibogaine resets opioid tolerance. Someone who returns to a previously tolerated dose afterwards faces overdose risk comparable to an opioid-naive person. This is among the best-documented dangers in ibogaine practice
• Stopping opioids abruptly to prepare for ibogaine is itself a hazard. The CDC's 2022 guideline warns specifically against rapid tapers and abrupt discontinuation
• Methadone is a potent QT-prolonging drug, and its long half-life means clearance before ibogaine takes considerably longer than most people expect

Anyone considering this route needs a prescribing clinician involved — not as a formality, but because the tapering itself is the part most likely to cause harm.

Because ibogaine is Schedule I in the United States, people seeking it travel to clinics in jurisdictions where it is unscheduled or tolerated — most commonly Mexico, and also Costa Rica and Portugal. Oversight varies widely, and none of these programmes are approved chronic pain treatments.

A responsibly run programme should include, at minimum:

• 12-lead ECG with QTc measurement, and cardiology clearance for any abnormality
• Comprehensive metabolic panel with serum potassium and magnesium, corrected to normal range before dosing
• Liver and renal function testing, and full blood count
• Complete medication reconciliation, screening for QT-prolonging and serotonergic agents — unusually important in chronic pain, where many patients take several of both
• CYP2D6 genotyping where available, to identify poor metabolisers with prolonged noribogaine exposure
• Continuous cardiac telemetry, extending well beyond the acute phase

In the published pain case report, the patient was under constant cardiac monitoring. The authors recorded asymptomatic ventricular extrasystoles at peak doses without haemodynamic instability.

One caveat deserves emphasis. Noribogaine's half-life is roughly 28–49 hours, and Koenig and Hilber documented ibogaine-associated deaths occurring 1.5 to 76 hours after ingestion. Monitoring periods of 12 or 24 hours are shorter than the documented risk window.

The acute experience involves several hours of intense psychoactive effects followed by extended recovery, commonly with profound ataxia, nausea, vomiting, and inability to stand unassisted. For someone whose pain condition affects mobility, or who has cervical or lumbar instability, that period carries fall and positioning risks generic protocols do not address.

Ibogaine's safety profile is dominated by one issue: cardiac electrophysiology. It is not theoretical, and a careful setting alone does not resolve it.

The mechanism. Ibogaine and noribogaine block hERG potassium channels in cardiomyocytes. Koenig and Hilber (Molecules, 2015) report an IC50 of approximately 4 µM for ibogaine and 3 µM for noribogaine — concentrations reached at therapeutic doses. hERG blockade prolongs repolarisation, lengthening the QT interval and raising the risk of torsades de pointes and cardiac arrest. Reported QTc values range from 480 ms to more than 700 ms, and that review documented roughly 22 fatalities temporally associated with ibogaine between 1990 and 2014.

Documented risk factors include hypokalaemia (present in every case report reviewed), hypomagnesaemia (about half), female sex, prolonged baseline QT, bradycardia, pre-existing cardiovascular disease, drug interactions, and CYP2D6 variants affecting metabolism.

Why chronic pain populations are a specific concern. This is where general ibogaine safety data meets routine pain care — and in most cases no interaction data exist at all:

• Tricyclic antidepressants (amitriptyline, nortriptyline) are first-line for neuropathic pain and are themselves QT-prolonging
• SNRIs (duloxetine, milnacipran) and SSRIs add serotonergic load; ibogaine is serotonergic, and serotonin toxicity is a recognised concern
• Methadone and tramadol both prolong QT; tramadol is also serotonergic and lowers seizure threshold
• Ondansetron, widely used for nausea, is QT-prolonging — relevant given ibogaine's pronounced emetic effect
• Gabapentinoids and opioids compound sedation and respiratory depression
• Diuretics can lower potassium, the single most consistent factor in ibogaine fatalities

Generally accepted absolute contraindications include long QT syndrome, structural heart disease, heart failure, recent myocardial infarction, uncorrected electrolyte abnormalities, significant hepatic or renal impairment, pregnancy, and active psychosis or bipolar I disorder.

Nothing is known about the long-term safety of the daily maintenance dosing described in the pain case report.

Legal status. Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act — denoting high abuse potential, no currently accepted medical use, and lack of accepted safety under medical supervision. It is not approved for chronic pain anywhere in the world. Registered ibogaine trials target opioid use disorder and neuropsychiatric conditions, not pain.

What would actually advance the question:

• Preclinical work on ibogaine itself in standard pain models — chronic constriction injury, spared nerve injury, chemotherapy-induced neuropathy. Almost all existing animal pain data concern analogues, not the parent compound
• Whether analgesia can be separated from psychoactivity. The analogue programmes exist precisely because this has not been shown for ibogaine
• A prospective registry using validated instruments and blinded assessors. People are already travelling for treatment; systematic data collection would outperform scattered case reports
• Controlled trial design, which is genuinely hard: blinding an intensely psychoactive drug in a subjectively rated condition may require an active comparator
• Interaction studies with tricyclics, SNRIs, gabapentinoids, and methadone, plus durability and chronic-dosing safety data

The honest bottom line. For a condition affecting roughly a quarter of American adults, the evidence for ibogaine for chronic pain consists of a single uncontrolled case report published by the treating clinic, a 1999 patent, and rodent studies of chemically modified derivatives. Set against that is a documented, potentially fatal cardiac risk amplified by medications many pain patients already take.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. Decisions about pain management — including whether to start, continue, taper, or stop any analgesic or opioid — should be made with a treating clinician. Abrupt discontinuation of long-term opioid therapy carries documented risk of harm.